David Goltzman

Biographical Sketch

David Goltzman is Antoine Massabki Professor of Medicine and Physiology at McGill University and Senior Physician in the Endocrine Division of the Department of Medicine of the McGill University Health Centre. He is a past Chair of the Department of Medicine and of the Department of Physiology. For his research contributions, Dr Goltzman has received various honours and awards, including the Aurbach Award of the US Endocrine Society, the Raisz Award of the American Society for Bone and Mineral Research (ASBMR), fellowship in the Royal Society of Canada and in the Canadian Academy of Health Sciences, the Order of Canada, an honorary professorship from Nanjing University and the degree of Doctor Honoris Causa from the University of Athens. He is a past President of the ASBMR, the Canadian Society of Clinical Investigation and the Canadian Society of Endocrinology and Metabolism.

Keywords

Hormonal regulation of mineral and skeletal homeostasis.

Research or Clinical Activities

Dr. Goltzman`s research has been unique in defining basic mechanisms relevant to the regulation of mineral and skeletal metabolism, while also providing new clinical concepts of metabolic bone disease, including osteoporosis, renal osteodystrophy, and cancer and bone. He has made many important contributions to our knowledge of parathyroid hormone (PTH), PTH related peptide and vitamin D, which have had major impact on our understanding of the pathophysiology.and treatment of a variety of metabolic bone diseases. He has also been principal investigator of the Canadian Multicentre Osteoporosis Study (CaMos) which examines the demographics, development, risk factors and outcomes of osteoporosis. His publications (more than 400 peer-reviewed original publications) have been cited over 29,000 times (over 16,000 since 2016) with an h-index of 102 (Google Scholar). He also pursues clinical activity in metabolic bone disease and general endocrinology and teaches at the undergraduate and postgraduate levels.

Selected Recent Publications

Goltzman D. Pathophysiology of Hypercalcemia. Endocrinol Metab Clin North Am. 2021 Dec;50(4):591-607

Papaioannou A, Adachi JD, Berger C, Jiang Y, Barron R, McGinley JS, Wirth RJ, Anastassiades TP, Davison KS, Hanley DA, Ioannidis G, Kaiser SM, Kovacs CS, Leslie WD, Morin SN, Prior JC, Towheed T, Goltzman D. Testing a theoretical model of imminent fracture risk in elderly women: an observational cohort analysis of the Canadian Multicentre Osteoporosis Study.Osteoporos Int. 2020 Jun;31(6):1145-1153.

Chen L, Yang R, Qiao W, Zhang W, Chen J, Mao L, Goltzman D, Miao D.1,25-Dihydroxyvitamin D exerts an antiaging role by activation of Nrf2-antioxidant signaling and inactivation of p16/p53-senescence signaling. Aging Cell. 2019 Jun;18(3):e12951.

Morris JA, Kemp JP, Youlten SE, et al An atlas of genetic influences on osteoporosis in humans and mice. Nat Genet. 2019; 51:258-266

Nguyen-Yamamoto L, Tanaka KI, St-Arnaud R, Goltzman D. Vitamin D-regulated osteocytic sclerostin and BMP2 modulate uremic extraskeletal calcification. JCI Insight. 2019 Jul 11;4(13):e126467

Samelson EJ, Broe KE, Xu H, et al Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. Lancet Diabetes Endocrinol. 2019 Jan;7(1):34-43.

PubMed Publications – D. Goltzman